Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 18, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update

SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
May 18, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy to Participate in the H.C. Wainwright Global Investment Conference

SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...
February 22, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus

OTO-313 Phase 2 trial is fully enrolled ahead of scheduleTop-line results for all timepoints expected in mid-2022 SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a...
February 17, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update

SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
January 06, 2022 07:51 ET | Source: Otonomy, Inc.

Otonomy Reports Corporate and Product Pipeline Update

Multiple clinical trial readouts for OTO-313 in tinnitus and OTO-413 in hearing loss expected during 2022 Current capital funds operations into second half of 2023 SAN DIEGO, Jan. 06, 2022 (GLOBE...
January 03, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy to Participate in the H.C. Wainwright BioConnect Conference

SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...
November 25, 2021 09:28 ET | Source: Research and Markets

Worldwide Hearing Aid Industry to 2026 - Featuring Sonova Holding, Demant and Starkey Among Others

Dublin, Nov. 25, 2021 (GLOBE NEWSWIRE) -- The "Global Hearing Aid Market (2021 Edition) - Analysis By Hearing Devices (BTE, ITE, RIC, ITC and CIC), Type of Hearing Loss, Technology, Patient Type, By...
November 10, 2021 16:18 ET | Source: Otonomy, Inc.

Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update

OTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022Enrollment nearly complete in OTO-413 Phase 2a cohort in hearing loss with results moved forward to early in second quarter...
November 03, 2021 07:30 ET | Source: Otonomy, Inc.

Otonomy to Report Third Quarter 2021 Financial Results and Provide Corporate Update

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
October 27, 2021 07:30 ET | Source: Otonomy, Inc.

Otonomy Announces Multiple Presentations at Neuroscience 2021 Meeting

Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss Supportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection...